Ensysce Biosciences, Inc.
No SEC Form 4 filings for $ENSC in the last 30 days.
Ensysce Biosciences (NASDAQ:ENSC) completed its acquisition of Cy Biopharma, adding clinical-stage pain drug CY200 for Complex Regional Pain Syndrome with FDA Orphan Drug Designation. Ensysce secured up to $77 million via cash contribution, private placement, and milestone funding. Cy Biopharma shareholders are expected to own about 74.94% after preferred conversion.
Biotech gainers included Creative Medical (CELZ), up 71.95% after a new U.S. patent for exosome-based immunotherapy for Type 1 diabetes. Braveheart Bio (BRVE) jumped 65.56% on its Nasdaq debut. Iovance (IOVA) rose 43.09% after Q2 product revenue rose 66% to about $99M. Sight Sciences (SGHT) gained 27.75% after raising 2026 revenue guidance to $88M-$92M.
Ensysce Biosciences, Inc. (ENSC) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 ex2-1.htm EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among: ensysce biosciences, Inc., a Delaware corporation; PHRMA MERGER SUB I, INC., a Delaware corporation; PHRMA MERGER SUB II, LLC, a Delaware limited liability company; and Cy Biopharma, Inc., a Delaware
Over the past 7 days, alphai's AI scored 3 news stories mentioning ENSC (Ensysce Biosciences, Inc.). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.
Recent ENSC coverage spans financial news, mergers & acquisitions and market movers.
The deal adds an orphan-designated clinical pain asset (CY200) and reduces near-term funding uncertainty, but it also creates major dilution risk from Cy shareholders converting to majority ownership.
Deal completion plus milestone-linked financing can improve runway and pipeline optionality, but also introduces execution and dilution risk.
Deal completion is a direct capital-structure and business-model catalyst for ENSC, likely shifting risk from standalone operations to post-merger ownership/consideration mechanics.
The filing signals leadership turnover that can affect near-term execution and governance, but it provides no operational metrics or financial guidance.
The article flags a sharp short-interest surge alongside very low days-to-cover, raising squeeze/volatility risk for ENSC.
alphai scores every news story that mentions ENSC with an AI model for sentiment and relevance, and aggregates insider trades from Ensysce Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Ensysce Biosciences (NASDAQ:ENSC) completed its acquisition of Cy Biopharma, adding clinical-stage pain drug CY200 for Complex Regional Pain Syndrome with FDA Orphan Drug Designation. Ensysce secured up to $77 million via cash contribution, private placement, and milestone funding. Cy Biopharma shareholders are expected to own about 74.94% after preferred conversion.
5 min readBiotech gainers included Creative Medical (CELZ), up 71.95% after a new U.S. patent for exosome-based immunotherapy for Type 1 diabetes. Braveheart Bio (BRVE) jumped 65.56% on its Nasdaq debut. Iovance (IOVA) rose 43.09% after Q2 product revenue rose 66% to about $99M. Sight Sciences (SGHT) gained 27.75% after raising 2026 revenue guidance to $88M-$92M.
3 min readEnsysce Biosciences, Inc. (ENSC) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 ex2-1.htm EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among: ensysce biosciences, Inc., a Delaware corporation; PHRMA MERGER SUB I, INC., a Delaware corporation; PHRMA MERGER SUB II, LLC, a Delaware limited liability company; and Cy Biopharma, Inc., a Delaware
6 min readEnsysce Biosciences, Inc. (ENSC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001716947 0001716947 2026-07-15 2026-07-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
4 min readEnsysce Biosciences (NASDAQ:ENSC) reported a sharp rise in short interest: 814,605 shares as of May 15, up from 52,730 on April 30, with about 5.7% of shares sold short and a days-to-cover ratio of 0.1 (based on average daily volume). The stock traded at $0.30. The company reported May 15 quarterly EPS of -$0.52 and revenue of $0.96M.
2 min readEnsysce Biosciences reported a Q4 net loss of $2.8 million, showing a narrowing compared to previous periods. This financial update indicates a positive trend for the company's fiscal performance. The information was provided by Reuters and cited by TradingView News.
2 min readEnsysce Biosciences ( NASDAQ:ENSC ) , a biotechnology company developing abuse-deterrent opioid therapies, reported its second-quarter results on August 13, 2025. The quarter's biggest news included the launch of a pivotal Phase 3 clinical trial for its lead program, PF614, and full enrollment in ...
3 min readEnsysce stock trades up with 26.79 million volume, far exceeding the 81.23K average. PF614-MPAR showed reduced oxycodone release in overdose scenarios during trials. Don't face extreme market conditions unprepared.
3 min read
